Gilead Confronts New Attacks On Pricing, Patents
This article was originally published in Scrip
Executive Summary
Gilead Science Inc. was slammed with a pair of attacks against the way it markets its hepatitis C virus (HCV) drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir-sofosbuvir) and its HIV/AIDS medicines containing tenofovir – with one punch coming from a new foe, the Massachusetts Attorney General Maura Healey, and the other from one of its longtime antagonists, the AIDS Healthcare Foundation (AHF).